Estimation of Ribociclib and Letrozole in Solid Dosage form (Tablet): A Novel Analytical Method | Chapter 9 | Current Overview on Pharmaceutical Science Vol. 9

An attempt was created to develop a plain, rapid, and corroborated method for the concurrent estimation of ribociclib and letrozole together tablet portion of drug or other consumable form.Inhibitors of cyclin D1/CDK4 (Cyclin-dependent kinase 4) [2] and CDK6 (Cyclin-weak kinase 6) [2] are found in Ribociclib, which is retailed by Novartis under the brand names Kisqali and Kryxana. This drug is used to treat some types of feelings cancer. The mixture of aromatase inhibitors and fulvestrant Inhibitors of cyclin D1/CDK4 (Cyclin-dependent kinase 4) and CDK6 (Cyclin-reliant kinase 6) are found in Ribociclib, This drug is used to treat few types of breast malignancy. The combination of aromatase inhibitors and fulvestrant.The chromatographic break-up was carried out on Waters, proportion C18 (150 mm×4.6 mm with 3.5 µm), travelling phase secondhand was a mixture of safeguard and acetonitrile in the ratio of 80:20, accompanying flow rate of 1ml/min and dose volume of 10 µL for the assay. The detection was finished using PDA at 260 nm, accompanying run time of 5 brief time period. The retention opportunity for the drugs ribociclib and letrozole was detected expected 2.648 min and 3.151 brief time period, respectively. The pattern was validated in accordance with ICH guidelines.The extent of object of letrozole and ribociclib was observed expected in the range of 0.50–7.50 and 40.01–600.15, Correlation coefficient (r2) 0.999 and 0.9983, individually. Accuracy for ribociclib and letrozole is carried out by repeatable concentrations of 50%, 100%, and 150. Validation determinants of robustness and masculinity were detected to be in limits.The grown method was plain, rapid, and logical; it can be secondhand for the simultaneous belief of ribociclib and letrozole tablet portion of drug or other consumable form in routine analysis. The approved method maybe used for the routine reasoning of both the drugs from size and different formulations and will help in healing drug monitoring (TDM) and bioavailability studies.

Author(s) Details:

Bhagyalata Satapathy,
The Tamil Nadu Dr. M.G.R Medical University, India.

Chaitanya Bangari,
The Tamil Nadu Dr. M.G.R Medical University, India.

Please see the link here: https://stm.bookpi.org/COPS-V9/article/view/10178